Get the Stockscreener App
87.07
1.81%
-1.67
Illumina Inc stock is traded at $87.07, with a volume of 783.49K.
It is down -1.81% in the last 24 hours and down -33.54% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$88.74
Open:
$88.7
24h Volume:
783.49K
Relative Volume:
0.35
Market Cap:
$13.91B
Revenue:
$4.39B
Net Income/Loss:
$-1.58B
P/E Ratio:
-8.742
EPS:
-9.96
Net Cash Flow:
$546.00M
1W Performance:
-7.27%
1M Performance:
-33.54%
6M Performance:
-33.11%
1Y Performance:
-37.99%
1-Day Range:
$86.70
$88.81
1-Week Range:
$86.70
$96.88
52-Week Range:
$86.70
$156.66
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
87.09 | 13.91B | 4.39B | -1.58B | 546.00M | -9.96 |
|
TMO
Thermo Fisher Scientific Inc
|
525.74 | 198.19B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
207.72 | 148.92B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
128.25 | 36.52B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IDXX
Idexx Laboratories Inc
|
439.88 | 35.63B | 3.90B | 887.87M | 798.08M | 10.67 |
|
IQV
Iqvia Holdings Inc
|
188.27 | 33.12B | 15.41B | 1.37B | 2.11B | 7.50 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Feb-10-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-07-25 | Downgrade | TD Cowen | Buy → Hold |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-12-24 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Aug-28-24 | Upgrade | Argus | Hold → Buy |
| Aug-16-24 | Upgrade | Daiwa Securities | Neutral → Buy |
| Aug-14-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-14-24 | Upgrade | TD Cowen | Hold → Buy |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
| Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-28-23 | Initiated | Bernstein | Underperform |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jan-25-23 | Downgrade | Argus | Buy → Hold |
| Jan-05-23 | Initiated | Scotiabank | Sector Perform |
| Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-18-22 | Upgrade | Stifel | Hold → Buy |
| Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-21 | Initiated | Barclays | Underweight |
| Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-22-20 | Downgrade | Stifel | Buy → Hold |
| Sep-22-20 | Downgrade | UBS | Buy → Neutral |
| Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
Here's How Much $1000 Invested In Illumina 20 Years Ago Would Be Worth Today - Benzinga
Illumina stock touches 52-week low at $87.29 amid market shifts - Investing.com
Biochips Market Generated Opportunities, Future Scope 2025-2032 | PerkinElmer, Inc., Fluidigm Corporation, Illumina - openPR
Bank of New York Mellon Corp Has $454.62 Million Holdings in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Illumina, Inc. (NASDAQ:ILMN) Stock Holdings Decreased by Fjarde AP Fonden Fourth Swedish National Pension Fund - MarketBeat
ARK Investment Management LLC Takes Position in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Y Intercept Hong Kong Ltd Boosts Stock Position in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
National Pension Service Decreases Stake in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Los Angeles Capital Management LLC Sells 41,352 Shares of Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Sabal Trust CO Buys Shares of 7,266 Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Impax Asset Management Group plc Sells 6,320 Shares of Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
FourThought Financial Partners LLC Takes Position in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Weil Company Inc. - MarketBeat
Tariffs, Cut Funding Spur Illumina’s Worst Month in 23 Years - Yahoo Finance
Illumina's Challenging February: Tariffs, Competition, and Funding CutsNews and Statistics - IndexBox, Inc.
AI Models Writing DNA and Designing Enzymes, Some Pre-AGBT News - Genetic Engineering & Biotechnology News
Investor Network: Illumina, Inc. to Host Earnings Call - ACCESS Newswire
HSBC downgrades Illumina on China risks, funding concerns - Investing.com
China Tariffs, Cut Funds Spur Illumina’s Worst Month in 23 Years - Bloomberg
Illumina to lay off 96 San Diego employees - MedTech Dive
What Makes Illumina (ILMN) an Attractive Opportunity? - Insider Monkey
Here's Why Illumina (ILMN) is a Strong Value Stock - Yahoo Finance
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Illumina, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineILMN - ACCESS Newswire
SHAREHOLDER ALERT: Potential Recovery for Illumina, Inc. (ILMN) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Illumina, Inc. to Host Earnings Call - ACCESS Newswire
Illumina, Inc. (NASDAQ:ILMN) Shares Bought by Hardman Johnston Global Advisors LLC - MarketBeat
INVESTOR ALERT: Potential Recovery for Illumina, Inc. (ILMN) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Strength in numbers: How the Rare Barometer supports the rare disease community - Illumina
Synthetic Biology Market Projected To Witness Substantial Growth, 2025-2032: GenScript, Amyris, Illumina, - EIN News
Metagenomics Market: Gaining Unprecedented Momentum | Illumina, PerkinElmer - openPR
The Jackson Laboratory advances precision medicine with an end-to-end workflow - Illumina
Roche SBX announcement creates more uncertainty for Illumina, says RBC - MSN
The Jackson Laboratory advances precision medicine with an end-to-end NGS workflow - Illumina
Key Digital Genome Market Trend 2025-2034: Innovative Products In The Digital Genome Market Illumina's Nova... - WhaTech
Truist Financial Corp Sells 2,989 Shares of Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Global Long Read Sequencing Market Detailed In New Research Report 2025 | Illumina Inc., Pacific Biosciences, - openPR
Liquid Biopsy Market Worth US$11.3 billion at a robust CAGR of 11.9% | MarketsandMarkets™. - GlobeNewswire Inc.
$1000 Invested In Illumina 20 Years Ago Would Be Worth This Much Today - Benzinga
What Makes Illumina (ILMN) a Long Term Bet? - MSN
Illumina’s high-throughput single-cell CRISPR prep makes gene editing a reality - Illumina
Ieq Capital LLC Boosts Stock Holdings in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Objective long/short (ILMN) Report - news.stocktradersdaily.com
Illumina reveals expansive multiomics technology roadma By Investing.com - Investing.com Nigeria
Illumina (ILMN): Building The Picks And Shovels Of the Genomic Age - Securities.io
ILMN Stock Might Rise From Collaboration With Broad Clinical Labs - Yahoo Finance
Illumina transforms multiomic research with new technologies to unlock deeper understanding of biology - PR Newswire
Illumina reveals expansive multiomics technology roadma - Investing.com
Illumina Innovation Roadmap - Illumina
Can Illumina's New Million-Cell Analysis Technology Revolutionize CRISPR Research? - StockTitan
Biochips Market Growth | Trends, Size & Forecast 2024-2031 | Abbott Laboratories, PerkinElmer Inc., Illumina, Inc. - openPR
Trump’s Early Policy Moves Create New Headaches for This Biotech Heavyweight - The Wall Street Journal
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.07%
2.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):